The FDA provided pivotal agreement on the Phase 3 design for BMD.
3 reports, 1 independent
Updated Aug 1
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA provided pivotal agreement on the Phase 3 design for BMD.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.
- FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
- FDA reviewed protocol amendment and interim safety data for a company's product.
- Emmaus Life Sciences is conducting Phase 3 trials for an Endari drug, preceding future FDA submission.
Coverage
Newest first; wire copies grouped- GlobeNewswireEntera Bio Announces Second Quarter 2025 Financial Results and Business Updates FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and c
- GlobeNewswireEntera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio